All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Multiple Myeloma Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View multiple myeloma content recommended for you

EHA 2023

Share:

Jun 8, 2023

X post image

11 Jun 2023

#EHA2023 | POSTER | Efstathios Kastritis shares the treatment outcomes of pts with MM <50 years of age, from the Balkan Myeloma Study Group. 5-year OS rate 76% vs 71% for <50 and ≥50 years pts, respectively. Lower-risk disease recorded in pts <50 years of age. #mmsm

X post image

11 Jun 2023

#EHA2023 | Michaela Liedtke shares 18-mo safety and tolerability data from the phase 2 study of CAEL-101 in combination with SoC anti-PCD therapy, for the treatment of AL amyloidosis. 60% had TEAEs grade ≥3, 52% had SAEs. 23% cardiac-evaluable pts responders. #amyloidosis

X post image

11 Jun 2023

#EHA2023 | Luciano Costa @End_myeloma shares a final analysis of the MASTER trial on quadruplet Dara-KRd, ASCT and MRD-modulated consolidation in NDMM. MRD neg 81%. PFS 88%, 79%, 50% in 0, 1 and 2+ HRCA, OS 94%, 92% and 75%. #mmsm #myeloma

X post image

11 Jun 2023

#EHA2023 | Nikhil Munshi @DanaFarber presents the final results from the CARTITUDE-1 trial of cilta-cel in RRMM. Median PFS 34.9 months, ORR 97.9%. Median OS not reached, at 36-mo estimated OS 62.9%. #mmsm #myeloma

X post image

11 Jun 2023

#EHA2023 | POSTER | Karthik Ramasamy @UniofOxford presents the treatment patterns of 3rd LOT RRMM patients in Germany, Italy, UK, France and Spain. 3rd LOT predominantly IMiD based with a recent shift toward triplet regimens recorded. #mmsm #myeloma

X post image

11 Jun 2023

#EHA2023 | POSTER | Roman Hajek shares the survival outcomes of len-refractory vs len-exposed RRMM patients. Median OS 21.5 vs 36.6 months for len-refractory vs exposed, respectively. In 2nd LOT, OS remained significantly worse in len-refractory cohort. #mmsm #myeloma

X post image

11 Jun 2023

What better way to finish off a weekend of inspiring and exciting presentations at #EHA2023 than with the late breaking abstract session. Many congratulations to all speakers! @EHA_Hematology #medicalcongress #multiplemyeloma #MMsm

X post image

11 Jun 2023

#EHA2023 | POSTER | Jun Ho Yi, @CAU_News shares the RW outcomes of penta-exposed MM patients treated with selinexor and dexamethasone (XD) in Korea. ORR 25%, median PFS 2.1 months, median OS 4.6 months. #mmsm #myeloma

X post image

10 Jun 2023

#EHA2023 | POSTER | Xuelin Dou presents on MAGE-C1/CT7 as a prognostic tool for MRD detection in MM. Peri-ASCT MAGE-C1/CT7 status predicted OS and PFS compared with MRD.
#mmsm #myeloma

X post image

10 Jun 2023

#EHA2023 | POSTER | Amaya Llorente Chávez @incmnszmx shares data on extramedullary MM (EMM) in Mexico. OS 77.8mo, 52mo and 32.7mo in MM, EMMO and EMMH, respectively. EMM worse OS and PFS compared with MM. EMMH resulted in poorest overall outcomes. #mmsm #myeloma

X post image

10 Jun 2023

#EHA2023 | Meletios A. Dimopoulos, @uoaofficial shares data from the DREAMM-3 trial of belantamab mafodotin vs pomalidomide plus dexamethasone for RRMM. Median PFS 11.2mo vs 7.2mo. PFS HR not significant. ORR 41% vs 36% in belamaf and Pd. #mmsm #myeloma

X post image

10 Jun 2023

#EHA2023 | Efstathios Kastritis shows data from the phase 2 EMN27 trial of belantamab mafodotin monotherapy in pts with RRAL amyloidosis. Overall ORR 60%, 56% in pts with prior dara exposure. Median time to response 0.5mo. #amyloidosis

X post image

10 Jun 2023

#EHA2023 | Hans C. Lee presents data from the phase 2 LINKER-MM1 trial of dosing for linvoseltamab in RRMM. ORR was 71% vs 50% in the 200mg and 50mg cohorts, respectively. CRS was the most common TEAE, in 45% and 55% in 200mg and 50mg. #mmsm #myeloma

X post image

10 Jun 2023

#EHA2023 | @Mohty_EBMT presents follow up data from the phase 2 MAGNETISMM-3 trial of elranatamab in RRMM. 61% ORR, MRD neg 89.7%. 70.7% experienced grade 3/4 TEAEs, most commonly hematologic. #mmsm #myeloma

X post image

10 Jun 2023

#EHA2023 | @DrKrinaPatel presents an analysis of ide-cel in TCE RRMM, from the KARMMA-3 trial. Ide-cel use resulted in increased ORR, CRR and PFS compared with SoC regardless of high-risk status. #mmsm #myeloma

X post image

10 Jun 2023

#EHA2023 | @H_Einsele shares results from the phase 3 CARTITUDE-4 trial of cilta-cel vs SoC in len-refractory MM. ORR 99% with 86% ≥CR and 72% MRD neg in cilta-cel as-treated group. #mmsm #myeloma

X post image

10 Jun 2023

Huge congratulations to Multiple Myeloma Hub steering committee member @H_Einsele, selected for one of the #EHA2023 best abstracts awards!
Abstract S100: First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory MM
#mmsm

X post image

10 Jun 2023

CONGRESS| Not much room left in the plenary abstracts session at #EHA2023! Looking forward to the presentations on the best scoring abstracts from the whole congress #MMsm #MultipleMyeloma #medicalcongress

X post image

10 Jun 2023

#EHA2023 | POSTER | @dra_v_hungria shares data from the MYLACRE study of MM in Latin America. Novel therapy adoption is lower in Latin America with high attrition rates recorded between LOTs. Unmet need in early LOTs for pts with no health insurance. #mmsm #myeloma

X post image

10 Jun 2023

CONGRESS #EHA2023 | Jeffrey Matous @ResearchUGent reports on the MAJESTEC-2 phase Ib study of teclistamab+ nirogacestat in RRMM. N=28. Any AE =100%, grade 3/4 =92.9%. 5 grade 5 TEAEs. 74% ORR, 52% ≥CR across all dose levels. 87.2% responders remained in response at 12 mos #MMsm

X post image

10 Jun 2023

CONGRESS #EHA2023 | @SusanBal9 @uabmedicine covers BMS-986393 a GPCR class 5 targeted CAR T-cell for RRMM. N=67. ORR = 86.5% overall, with a CRR = 38.5% across all doses. Median follow-up was 6.0 months (range, 1–20.2). Best ORR was 96.3% in BCMA naive pts (n=27) #MMsm #MYELOMA

X post image

10 Jun 2023

CONGRESS #EHA2023 | @Nbahlis @Charb_Cancer speaks about TRIMM-2 results: talquetamab + daratumumab in RRMM. N=65. ORR was 71.4% (57.1% ≥VGPR; 42.9% ≥CR) at 0.4mg/kg QW. ORR=84.0% in 0.8 mg/kg Q2W (74% ≥VGPR; 52% ≥CR). Responses deepened over time. #MMsm #MYELOMA

X post image

10 Jun 2023

CONGRESS #EHA2023 | Cyrille Touzeau @CHUnantes presents the results of MonumenTAL-1 a phase II study of talquetamab for RRMM. N=339. In the pivotal cohorts, ORR was 74.1% (QW, 18.8 mo mF/U) & 71.7% (Q2W, 12.7 mo mF/U), with ≥VGPR in 59.4% (QW) & 60.7% (Q2W). #MMsm #myeloma

X post image

10 Jun 2023

#EHA2023 | Albert Oriol discusses how to sequence therapy for pts by their individual profile. He provides indicators for poor-response and strategies to advance to further LOTs. CAR T may be considered in pts with no active infections and low tumor burden. #mmsm

X post image

10 Jun 2023

CONGRESS #EHA2023 | María-Victoria Mateos @mvmateos @Salud_JCYL reports on the REDIRECTT-1 study of teclustamab+ talquetamab in patients with RRMM. N=93. ORR was 86.6% among all pts & 96.3% at optimal phII dose. For pts with EMD= 71.4%. ≥CR= 40% all dose levels. #MMsm #myeloma

X post image

10 Jun 2023

#EHA2023 | Salomon Manier @CHU_Lille shares efficacy and safety data on BCMA targeted drugs: CAR T, bispecifics and antibody-drug conjugates. Future directions of CAR T cells include CART-ddBCMA, dual targeting CAR T and reduced manufacturing times. #mmsm

X post image

10 Jun 2023

#EHA2023 |@DoctorAKrishnan presents on novel targets and drugs in RRMM. GPRC5D and FcRH5 and the drugs targeting them are highlighted. Novel agents in CD38 refractory pts, include IGM-2644 and CD38-BIONIC. #mmsm #myeloma

X post image

10 Jun 2023

#EHA2023 | Michel Delforge, Pieter Sonneveld and Maria Gavriatopoulou review good practice guidelines for the management of MM. Key clinical trials that have influenced these guidelines are highlighted, with a patient case to demonstrate the application of these guidelines. #mmsm

X post image

9 Jun 2023

#EHA2023 | POSTER | Salomon Manier, @CHU_Lille shares data on the safety and efficacy of elranatamab monotherapy in RRMM with prior BCMA exposure.
ORR 46%, median PFS 5.5 mo, median OS 12.1 mo, manageable toxicities, no new safety signals. #mmsm #myeloma

X post image

9 Jun 2023

RT @lymphomahub: CONGRESS|#EHA2023 Fantastic presentations and discussions from our joint Lymphoma Hub and @MM_Hub symposium discussing the…

X post image

9 Jun 2023

#EHA2023 | Wassilis Bruins @amsterdamumc shares data on the impact of immunological aging on clinical outcomes in MM. Older pts displayed a distinct T cell profile compared with younger pts. A subset of older pts with younger T cell profile demonstrated superior survival. #mmsm

X post image

9 Jun 2023

#EHA2023 | Eric Letouzé presents two case studies on the mechanisms of acquired BsAb resistance in RRMM pts receiving talquetamab. Mechanisms highlighted include: multiclonal genetic resistance from pre-existing GPRC5D deletion and epigenetic silencing of GPRC5D locus. #mmsm

X post image

9 Jun 2023

CONGRESS | #EHA2023 | @SonjaZweegman @amsterdamumc discusses age versus frailty as factors to determine risk and treatment strategy in MM. Frailty is highlighted as a more important factor for developing risk-adapted strategies in multiple myeloma than age alone. #mmsm #myeloma

X post image

9 Jun 2023

CONGRESS | #EHA2023 | Cyrille Touzeau @CHUnantes presents a decision tree to aid sequencing decisions in MM. Transplant eligibility and refractory status are highlighted as a key prognostic factors to determine sequencing pathways. #mmsm #myeloma

X post image

9 Jun 2023

CONGRESS| Great first live in person session at #EHA2023! Edward Laane presents EHA guidelines to aid patient reported outcomes in #multiplemyeloma trials. Kate Morgan followed up with patient advocacy considerations and finished with a panel discussion #MMsm #medicalcongress

X post image

9 Jun 2023

One hour to go! Don’t miss out on our CAR-T event today at #EHA2023.

Join us live at 16:15–17:45 CEST

Expert opinions on CAR-T in #multiplemyeloma and #lymphoma, real patient cases, and challenges!

⭐1 credit EBAH accreditation! ⭐

#lymsm #mmsm

X post image

9 Jun 2023

CONGRESS | #EHA2023 | Jesús San Miguel, @unav presents on the benefits and controversies of using MRD as an endpoint in clinical trials. He suggests MRD may be used to evaluate therapy efficacy and to make clinical decisions such as introducing early rescue intervention. #mmsm

X post image

7 Jun 2023

The #MM Hub will be virtually covering the #EHA2023 Hybrid Congress from June 8-11, 2023!  

Keep an eye on our socials for live updates throughout the congress!  

#cancertreatment #mmsm #multiplemyeloma

X post image

6 Jun 2023

With all of the exciting content being shared at #EHA2023, the @MM_Hub and our steering committee members have provided a list of top abstracts to look out for in #multiplemyeloma

Check it out 👉 https://t.co/S7ExCgh1l6

@EHA_Hematology #mmsm #myeloma

X post image

2 Jun 2023

One week to go! Join us in-person or online at #EHA2023 (16:15 CEST) to gain 1 EBAH credit!

📚The ins and outs of #CART cells in the real world. An expert roundtable hosted by the #Lymphoma Hub and the #MultipleMyeloma Hub📚

Visit the @ESHaematology booth (A124) for more info!

X post image

30 May 2023

RT @sci_ed_support: @sci_ed_support is facilitating an exciting CME symposium at #EHA2023!

Our #IME hubs @MM_Hub & @lymphomahub are hosti…

X post image

26 May 2023

Curious about #CAR-T? Join our interactive, open-table discussion on CAR T-cell therapy at #EHA2023!

🟣Ulrich Jäger (Chair)
🟣Kieron Dunleavy
🟣Shaji Kumar
🟣Doris Hansen
🟣Michael Hudecek

visit our page: https://t.co/7S6OhMPHiL

X post image

10 May 2023

💭What: The ins and outs of CAR T cells in the real world. An expert roundtable hosted by the Lymphoma Hub and the Multiple Myeloma Hub

📍Where: Frankfurt, Germany & Online
📅When: 16:15–17:45 CEST| 09 June

EBAC accreditation applied for!

#EHA2023 #lymsm #mmsm

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

EHA 2023 European Hematology Association

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox